Drug intelligence / Profile preview

[18F]CFPyPB

Development stage: Phase 1
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[18F]CFPyPB is a potent and selective radiolabeled positron emission tomography (PET) tracer targeting the glycine transporter 1 (GlyT1). GlyT1 is an important regulator of glycine levels in the synaptic cleft and has been identified as a promising target for drug development in schizophrenia and other central nervous system disorders. [18F]CFPyPB enables non-invasive imaging of GlyT1 distribution and occupancy in the brain, supporting both preclinical research and potential clinical evaluation of GlyT1-targeted therapies. The compound is synthesized using automated microfluidic systems to ensure high purity suitable for PET imaging applications[1][2].

Other names: [18F]-CFPyPB18F-CFPyPB

Targets

SLC6A9 (Glycine transporter type 1)

Beyond the preview

Go deeper on [18F]CFPyPB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]CFPyPB.

Explore the full profile